Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish Orphan Biovitrum (Sobi) along with its partner, A. Menarini Australia has announced the receipt of marketing authorisation for Kineret (anakinra) in Australia.
Subscribe to our email newsletter
Kineret has been approved for the treatment of systemic juvenile idiopathic arthritis (SJIA), which is a rare form of juvenile chronic arthritis that affects children up to 16 years of age.
Kineret is a recombinant protein drug that blocks the biological activity of IL-1a and IL -1b by binding to interleukin-1 type 1 receptor (IL-R 1), expressed in a variety of tissues and organs, and thereby blocking the interleukin-1 (IL-1) signalling.
IL-1 is a key mediator of inflammation and a significant contributor to autoinflammatory diseases.
Sobi business area Inflammation medical therapeutic area head Kristina Timdahl said: "We are pleased and encouraged by this approval which was achieved through a fruitful collaboration between physicians, regulators, and our development team including Menarini.
"We are looking forward to serving a wider group of patients in Australia going forward."
About 100 of 100,000 children are affected by child arthritis, and of these 10-20% have the sJIA form, which is classified as an autoinflammatory disease.